Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis, and Post-Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50 × 10^9/L to 100 × 10^9/L
Sponsor: Incyte Corporation
Listed as NCT01348490, this PHASE2 trial focuses on MPN (Myeloproliferative Neoplasms) and remains completed. Sponsored by Incyte Corporation, it has been updated 14 times since 2011, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 9 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2019 — Feb 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2018 — May 2018 [monthly]
Recruiting PHASE2
-
May 2017 — Feb 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Corporation
For direct contact, visit the study record on ClinicalTrials.gov .